CompletedPhase 2NCT03679598

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Alabama at Birmingham
Principal Investigator: Mark T Dransfield, MD
University of Alabama at Birmingham
Intervention: Alvelestat (MPH966)(drug)
Enrollment: 63 enrolled
Eligibility: 18-80 years · All sexes
Timeline: 2019 – 2023

Study locations (10)

The University of Alabama at Birmingham Lung Health Center, Birmingham, Alabama, United States
UCLA, Los Angeles, California, United States
National Jewish Health, Denver, Colorado, United States
Columbia University, New York, New York, United States
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
Temple University, Philadelphia, Pennsylvania, United States
Medical University of South Carolina, Charleston, South Carolina, United States
The University of Texas Health Science Center at Tyler, Tyler, Texas, United States
University of Utah, Salt Lake City, Utah, United States

Collaborators

National Institutes of Health (NIH) · Mereo BioPharma · National Center for Advancing Translational Sciences (NCATS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03679598 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency →

← Back to all trials